Abclabs

Abclabs, also known as ABC Labs, originated in the spring of 2020 as a response to the COVID-19 pandemic, quickly becoming one of the largest pandemic laboratories in Sweden. The company was founded by Ahsan Amjad, Per Båtelson, Maria Rankka, and Ola Winqvist. It established a significant infrastructure for automated diagnostics, handling up to 28% of Sweden's total COVID-19 testing through partnerships with the Public Health Agency of Sweden and other healthcare providers. This effort was supported by public health contracts valued at over $180 million.

Pivoting from its initial focus, Abclabs now applies its diagnostic infrastructure to corporate and organizational testing. The company provides a fully digitized, end-to-end solution for alcohol and drug testing aimed at workplaces and treatment centers. This service utilizes Liquid Chromatography with tandem Mass Spectrometry (LC-MS/MS) for high accuracy and offers rapid result reporting. The laboratory is accredited according to ISO 15189:2012 standards. Its business model is primarily business-to-business (B2B), serving companies and organizations by helping them implement their drug and alcohol testing policies for employees, including pre-employment screening.

In addition to its commercial services, Abclabs is engaged in a research initiative named Artemis. This project focuses on building a comprehensive, time-resolved dataset of human health by utilizing long-term multi-omics and biochemistry data. The goal is to analyze this data to address fundamental questions about human biology and advance precision health.

Keywords: substance abuse screening, workplace drug testing, diagnostic services, automated laboratory, multi-omics research, biochemistry data, LC-MS/MS testing, precision health, corporate wellness, laboratory diagnostics, alcohol testing, employee screening, ISO 15189, end-to-end diagnostics, Human biology research, health data platform, Swedish biotech, healthcare diagnostics, molecular diagnostics